classification criteria, in annual follow-up (for a total of 165 patients/year) with Pulmonary Function Tests (PFTs), Health Assessment Questionnaire - Disability Index (HAQ-DI), Scleroderma Health Assessment Questionnaire (sHAQ) and Cochin Hand Function Score (CHFS). Hand disability index was assessed by CHFS and global disability index was assessed by HAQ and sHAQ. Patient reported arthritis activity was assessed by Visual Analog Scale for Arthritis Activity (VAS3). Based on the median of VAS3, patients were classified in two groups and the evaluation of global and hand disability index was performed for each group. Furthermore, we assessed the correlation between the change of VAS3 and the modification of disability scores (sHAQ, CHFS) over 12 months of follow-up. Following analysis of distribution, Spearman or Pearson Test were used to determine correlation coefficients, as appropriate (Prism 7).

Results: The median disease duration was 5 years (IQR 3-10). The median of VAS3 was 35 (IQR 2 - 66). In patients with VAS3 <35 and VAS3 ≥35 the HAQ-DI medians were 0.625 (IQR 0.25 - 1.5) and 1.75 (IQR 1.125-2.25) respectively, (p<0.001); and the CHFS medians were 4 (IQR 0 – 19) and 28 (IQR 10 – 46) respectively, (p<0.001). A significant correlation was observed between VAS3 and HAQ (r= 0.463, p<0.0001), SHAQ (r=0.651, p<0.0001) and the CHFS medians were 4 (IQR 0 – 19) and 28 (IQR 10 – 46) respectively, (p<0.001). A significant correlation was observed between VAS3 and CHFS (r=0.497 , p<0.0001); between ∆VAS3 and ∆SHAQ (r=0.493, p<0.0001), ∆VAS3 and HAQ (r= 0.463, p<0.0001); and the CHFS medians were 4 (IQR 0 – 19) and 28 (IQR 10 – 46) respectively, (p<0.001). A significant correlation was observed between VAS3 and CHFS (r=0.497 , p<0.0001); between ∆VAS3 and ∆SHAQ (r=0.493, p<0.0001).

Conclusion: This analysis of a monocentric non-selected population supports the key role of joint involvement in determining global patient reported functional and hand disability in SSc. Severity of musculoskeletal involvement should be carefully considered when interpreting PROs in patients with SSc.

References:

Disclosure of Interests: none declared

DOI: 10.1136/annrheumdis-2020-eular.3886

FRI0242

IMPACT OF PULMONARY ARTERIAL HYPERTENSION WITH OR WITHOUT INTERSTITIAL LUNG DISEASE ON SCLERODERMA: A RETROSPECTIVE COHORT STUDY FROM THE NATIONALWIDE SPANISH SCLERODERMA (RESCLE) AND PULMONARY ARTERIAL HYPERTENSION (REHAP) REGISTRIES

A. Guillén-del-Castillo1,2, M. López-Meseguer2,3, C. Tolosa4, A. Romás Broto2,3, D. Colunga Argüelles5, I. Blanco6,8, A. Castro8, R. López Reyes8, A. Marín Bañés2, I. Otero González2, V. Fonollola-Pia1, E. Sala Llinares2, P. Escribano Subías1,2,3, C. P. Simeón-Aznar1, Hospital Universitario Vall d’Hebron, Department of Pneumology, Barcelona, Spain; 2Hospital Universitari Parc Taulí, Department of Internal Medicine, Sabadell, Spain; 3Hospital Universitario Central de Asturias, Department of Internal Medicine, Oviedo, Spain; 4Hospital Clínico, Institut d’Investigacions Biomèdiques August Pi y Sunyer (IDIBAPS), Department of Pulmonary Medicine, Barcelona, Spain; 5Hospital Universitario Sant Joan, Department of Internal Medicine, Tarragona, Spain; 6Hospital Universitari i Politècnica La Fe, Department of Pneumology, Valencia, Spain; 7Hospital Clínico Universitario Lozano Blesa, IIS Aragón, Unit of Autoimmune Diseases, Department of Internal Medicine, Zaragoza, Spain; 8Hospital Universitario 12 de Octubre, Unit of Pulmonary Hypertension, Cardiology Department, Madrid, Spain; 9Hospital Universitario Son Espases, Department of Pneumology, Palma de Mallorca, Spain; 10Hospital Universitario A Coruña, Department of Pneumology, A Coruña, Spain; 11Hospital Universitario de Canarias, Department of Internal Medicine, Santa Cruz de Tenerife, Spain; 12Centro de Investigación Biológica en Red de Enfermedades Cardiovasculares (CIERBIC), Instituto de Salud Carlos III, Madrid, Spain

Background: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the major life-threatening complications in systemic sclerosis (SSc). Data on the impact of PAH and/or ILD in SSc patients (pts) is limited by their low prevalence.

Objectives: To assess differences in demographic/clinical characteristics of SSc pts according to presence of PAH and how these are affected by ILD. The impact on characteristics and survival of PAH + ILD was also assessed.

Methods: We compared data on SSc pts without PAH from the Spanish registry of patients with SSc (RESCLE) (SSc pts) and SSc pts with PAH from the Spanish registry of pts with PAH (REHAP) (SSc-PAH pts). Only data common in both registries were used to determine correlation coefficients, as appropriate (Prism 7).

Results: We compared data on SSc pts without PAH from the Spanish registry of patients with SSc (RESCLE) and SSc pts with PAH from the Spanish registry of pts with PAH (REHAP).

mean forced vital capacity [FVC, 81.2±20.6% vs. 93.6±20] and diffusing capacity for carbon monoxide [DLCO, 45.3±17.7% vs. 79.0±36.6%]). More patients had FVC/DLCO ≥1.4 (77.8% vs. 34.8%) or tricuspid regurgitation (91.4% vs. 46.1%) or pericardial effusion (30.0% vs. 5.1%). Mean systolic pulmonary artery pressure (sPAP) was higher (70.0±21.3 vs. 27.5±9.1 mmHg) (all respectively: P<0.001 for all). Prevalence of ILD on high-resolution computerized tomography was similar (44.9% [n=92] vs. 41.8% [n=422] in SSc pts; P=0.408). These differences were also found when splitting both cohorts according to the presence / absence of ILD. Compared to SSc-PAH pts without ILD (n=128), pts with PAH + ILD (n=92) had worse functional status (NYHA FC III/IV: 69.6% vs. 55.3% in SSc-PAH pts without ILD; P=0.039), lower mean FVC (70.9±21.9 vs. 86.2±18.6) and lower DLCO (39.4±17.0 vs. 49.1±17.9) both P<0.001. Five-year survival rate was 35% in SSc-PAH pts with ILD vs. 45% in SSc-PAH without ILD (P=0.444 [figure 1]).

Conclusion: PAH has a profound impact on functional status, pulmonary function and right ventricle function of SSc patients, independently of presence of ILD. Despite the deleterious effect of functional status and pulmonary function, in pts with SSc and PAH, presence of concomitant ILD has no impact on 5-year survival.

Figure 1. Survival rate estimates in SSc-PAH pts with and without ILD


DOI: 10.1136/annrheumdis-2020-eular.4302

FRI0243

SARCOPENIA IS ASSOCIATED WITH MALNUTRITION IN PATIENTS WITH SYSTEMIC SCLEROSIS

V. Hax1, R. Cavalheiro Do Espirito Santo2, E. Pena1, L. Rodrigues1, R. T. Pedro1, J. Miranda de Souza Silva1, N. Pamplona Bueno de Andrade1, A. A. Gasparin1, R. Xavier1, R. Menonça Da Silva Chakr2, Hospital de Clínicas de Porto Alegre, Department of Rheumatology, Porto Alegre, Brazil

Background: Sarcopenia is one of the major health problems in older patients and is defined as a progressive decrease in muscle mass and function 1. Sarcopenia has only rarely been studied in systemic sclerosis (SSc) and its impact in clinical characteristics of SSc is poorly investigated.

Objectives: To evaluate the associations between sarcopenia and clinical features in SSc patients.

Methods: Cross-sectional study, including 82 patients who met the ACR/EULAR 2013 classification criteria for SSc. Dual-energy X-ray absorptiometry, handgrip strength, and short physical performance battery were used to assess sarcopenia using the European Working Group on Sarcopenia in Older People’s (EWG- SOP) diagnostic criteria updated in 2019 3. Malnutrition was evaluated according to the European Society of Clinical Nutrition and Metabolism (ESPEN) 4, using the Malnutrition Universal Screening Tool (MUST) to screen risk for malnutrition.